# Excessive daytime sleepiness Market

> Excessive daytime sleepiness Market Research Report Information By Diseases (Obstructive Sleep Apnea (OSA), Narcolepsy), By Treatment (Devices, Therapeutic Drugs (Stimulants, Anti-Depressants, Amphetamine salts, Sodium oxybate)) By Distribution channels (Hospitals & Sleep Laboratories, Home Care Settings), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.2%
- **2024:** $ 5.97 Billion
- **2025:** $ 6.4 Billion
- **2035:** $ 12.83 Billion
- **Key Players:** Jazz Pharmaceuticals (IE), Eli Lilly and Company (US), Teva Pharmaceutical Industries Ltd. (IL), AstraZeneca (GB), Merck & Co., Inc. (US), Novartis AG (CH), Pfizer Inc. (US), Sanofi (FR), Amgen Inc. (US)

**Report ID:** MRFR/HC/18756-HCR · **Pages:** 128 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/excessive-daytime-sleepiness-market-20304

---

## Market Summary

## **Global Excessive daytime sleepiness Market Overview**

Excessive Daytime Sleepiness Market Sizewas valued at USD 5.2 Billion in 2022. The excessive daytime sleepiness market industry is projected to grow from USD 5.57 Billion in 2023 to USD 9.72 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.20% during the forecast period (2023 - 2032). Increase of population, awareness, healthcare expenditure diverse drug array and government reimbursement policies are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Excessive daytime sleepiness Market Trends**

Within the excessive daytime sleepiness (EDS) market, a notable trend is the continuous advancement of Application modalities. Emerging therapies, such as novel medications targeting specific neurotransmitters or innovative approaches like neuromodulator techniques, are gaining attention. As researchers delve deeper into understanding the underlying causes of EDS, the development of more effective and targeted Applications is on the rise. This trend reflects a commitment to addressing the complexities of excessive daytime sleepiness with a diverse range of therapeutic options, providing patients with tailored and improved solutions beyond traditional medications. This factor drives the market CAGR.

Additionally, an evolving trend in the excessive daytime sleepiness market involves the integration of wearable technology for monitoring and managing sleep-related conditions. [Wearable devices](../../../reports/wearable-medical-device-market-899) equipped with advanced sensors can track sleep patterns, monitor physiological parameters, and provide real-time data on sleep quality. This trend aligns with the growing demand for patient-centric solutions and facilitates more precise diagnostic measures. The incorporation of wearable technology not only aids in the accurate assessment of daytime sleepiness but also promotes a proactive approach to managing sleep disorders, fostering a trend towards personalized and data-driven healthcare interventions.

In response to the increasing prevalence of excessive daytime sleepiness and the need for accessible healthcare solutions, the market is witnessing a surge in telemedicine and virtual care platforms. Telehealth services allow patients to consult sleep specialists remotely, facilitating convenient access to expert advice and diagnostic evaluations. This trend is particularly relevant in the context of sleep disorders, as it overcomes geographical barriers and enhances patient engagement.

The integration of virtual care platforms in the excessive daytime sleepiness market represents a shift towards more patient-centric and inclusive healthcare delivery, ensuring that individuals can receive timely and comprehensive care regardless of their location. For instance, in February 2023, Pharmanovia announced the expansion of its neurology portfolio via a new licensing agreement with Axsome Therapeutics, Inc. Sunosi (solriamfetol), a first-in-class drug used to increase alertness and reduce EDS in individuals with narcolepsy or obstructive sleep apnoea (OSA), was expected to be marketed exclusively by Pharmanovia in Europe and the Middle East and North Africa (MENA).

Thus, driving the excessive daytime sleepiness market revenue.

## **Excessive daytime sleepiness Market Segment Insights:**

### **Excessive daytime sleepiness Diseases Insights**

The excessive Daytime Sleepiness market segmentation, based on Diseases includes Obstructive Sleep Apnea (OSA), Narcolepsy. The dominant category is Obstructive Sleep Apnea (OSA). This condition affects millions of individuals worldwide and is associated with various health complications, including cardiovascular diseases, hypertension, and impaired cognitive function. Due to its widespread prevalence and significant impact on overall health and well-being, OSA remains the primary focus of diagnosis, treatment, and management efforts within the Excessive Daytime Sleepiness market. Narcolepsy represents the fastest-growing category within the Excessive Daytime Sleepiness market.

While narcolepsy is less common than OSA, its recognition and diagnosis have been increasing in recent years due to greater awareness among healthcare professionals and the general public. Additionally, advancements in diagnostic techniques and treatment options for narcolepsy have contributed to its rapid growth within the Excessive Daytime Sleepiness market

**Figure 1: Excessive Daytime Sleepiness Market, by Diseases, 2022 & 2032 (USD Billion)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **Excessive daytime sleepiness Treatment Insights**

The excessive Daytime Sleepiness market segmentation, based on Treatment, includes Devices, Therapeutic Drugs (Stimulants, Anti-Depressants, Amphetamine salts, Sodium oxybate). The dominant category is Therapeutic Drugs, This encompasses a range of pharmaceutical interventions aimed at managing and alleviating symptoms associated with various sleep disorders contributing to excessive daytime sleepiness. Due to their widespread availability, established efficacy, and physician familiarity, therapeutic drugs remain the cornerstone of treatment strategies for managing sleep disorders and associated symptoms, making them the dominant category. Furthermore, Devices, particularly those related to therapy, represent the fastest-growing category in the Excessive Daytime Sleepiness market.

Due to increasing awareness about sleep disorders and technological advancements in device design and functionality, the demand for diagnostic and therapeutic devices is expected to surge.

### **Excessive daytime sleepiness Distribution channels Insights**

The excessive Daytime Sleepiness market segmentation, based on Distribution channels, includes Hospitals & Sleep Laboratories, Home Care Settings. The dominant category is Hospitals & Sleep Laboratories, These facilities serve as essential hubs for the diagnosis, treatment, and management of sleep disorders contributing to excessive daytime sleepiness. Hospitals with specialized sleep clinics and laboratories offer comprehensive sleep studies, including polysomnography and multiple sleep latency tests, to accurately diagnose conditions such as obstructive sleep apnea (OSA), narcolepsy, and restless legs syndrome. Home Care Settings emerge as the fastest-growing category in the distribution channels for the Excessive Daytime Sleepiness market.

With the increasing emphasis on patient-centered care and the growing popularity of home-based medical services, there is a rising trend toward providing sleep disorder management and treatment options in the comfort of patients' homes.

### **Excessive daytime sleepiness Regional Insights**

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American excessive daytime sleepiness market area will dominate this market, owing to an increased awareness and proactive initiatives in North America regarding the importance of sleep health and the consequences of untreated sleep disorders lead to higher rates of diagnosis and intervention. In addition, the growing number of establishing health clubs and fitness facilities will boost market growth in this region.

Further, the major countries studied in the market reportare The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure2: EXCESSIVE DAYTIME SLEEPINESS MARKET SHARE BY REGION 2022 (USD Billion)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Europeexcessive daytime sleepiness market accounts for the second-largest market share due to the excessive daytime sleepiness, influenced by factors such as lifestyle changes and work-related stress. Further, the Germanexcessive daytime sleepiness market held the largest market share and the UK excessive daytime sleepiness market was the fastest growing market in the European region

The Asia-Pacific Excessive daytime sleepiness Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due toimproving healthcare infrastructure and the growing awareness of sleep-related issues contributes to an enhanced diagnosis and Application landscape.Moreover, China’sexcessive daytime sleepiness market held the largest market share, and the Indianexcessive daytime sleepiness market was the fastest growing market in the Asia-Pacific region.

**Excessive daytime sleepiness Key Market Players & Competitive Insights**

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the excessive daytime sleepiness market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, excessive daytime sleepiness industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the excessive Daytime Sleepiness industry to benefit clients and increase the market sector. In recent years, the excessive daytime sleepiness industry has offered some of the most significant advantages. Major players in the excessive daytime sleepiness market, including Teva Pharmaceutical Industries Ltd.,GE Healthcare ,Jazz Pharmaceuticals,CompumedicsFisher & Paykel Healthcare,BIOPROJET,BMC Medical Co. Ltd.,Avadel Pharmaceuticals plc ,Cadwell Laboratories Inc. Ltd ,GlaxoSmithKline plc ,Braebon Medical Corporation ,Pfizer and others, are attempting to increase market demand by investing in research and development operations.

Harmony Biosciences Holdings, Inc. was founded in 2017 and is headquartered in Plymouth Meeting, Pennsylvania, USA. The company is dedicated to addressing unmet needs in sleep and CNS disorders, with a focus on bringing transformative Applications to patients.Harmony Biosciences is known for its emphasis on narcolepsy, a sleep disorder characterized by excessive daytime sleepiness. The company has developed and commercialized medications specifically designed to address symptoms associated with narcolepsy. Harmony Biosciences Holdings, Inc. initiated a Phase 3 trial evaluating the efficacy and safety of pitolisant in adult patients with idiopathic hypersomnia (IH), known as the INTUNE study.

NLS Pharma Ltd. is a biopharmaceutical company dedicated to advancing innovative Applications for central nervous system disorders, with a particular focus on narcolepsy. Privately held, the company is committed to addressing unmet medical needs in the field of neurological and psychiatric conditions through research, development, and the advancement of novel therapies. With a pipeline of drug candidates, NLS Pharma aims to contribute to improved outcomes for patients experiencing symptoms such as excessive daytime sleepiness and cataplexy.

NLS pharma Ltd. reported that the European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion to grant Orphan Drug Designation (ODD) for Mazindol ER (Quilience) for the Application of idiopathic hypersomnia (IH).

**Key Companies in the excessive daytime sleepiness market include**

**Excessive daytime sleepiness Industry Developments**

**August 2021:**For a new indication of Xywav, Jazz Pharmaceuticals Plc. received USFDA approval (calcium, magnesium, potassium, and sodium oxybates). It is an oral solution used to treat adult patients with idiopathic hypersomnia. It is the first medication that the USFDA has approved for unique use in idiopathic hypersomnia.

**March 2019:**Jazz Pharmaceuticals Plc. received FDA approval for a Sunosi (solriamfetol). The first and only dual-acting dopamine and norepinephrine reuptake inhibitor that has been authorized to treat excessive daytime sleepiness linked to narcolepsy or obstructive sleep apnea.

## **Excessive daytime sleepiness Market Segmentation:**

### **Excessive daytime sleepiness Diseases Outlook**

### **Excessive daytime sleepiness Treatment Outlook**

### **Excessive daytime sleepiness Distribution channels Outlook**

### **Excessive daytime sleepiness Regional Outlook**

## Market Drivers

### Rising Healthcare Expenditure

The increasing expenditure on healthcare services is a notable driver of the Excessive Daytime Sleepiness Market. As healthcare systems evolve, there is a growing emphasis on preventive care and the management of chronic conditions, including sleep disorders. In many regions, healthcare spending has risen significantly, with a focus on improving patient outcomes. This trend is reflected in the allocation of funds towards sleep clinics and specialized treatment programs aimed at addressing excessive daytime sleepiness. Moreover, insurance coverage for sleep studies and treatments is expanding, making it more accessible for patients. This financial commitment to sleep health is expected to bolster the Excessive Daytime Sleepiness Market.

### Advancements in Sleep Technology

Technological innovations in sleep monitoring and treatment are significantly influencing the Excessive Daytime Sleepiness Market. The introduction of wearable devices and mobile applications that track sleep patterns has empowered consumers to take charge of their sleep health. These technologies not only provide insights into sleep quality but also facilitate early detection of sleep disorders. Furthermore, advancements in therapeutic devices, such as continuous positive airway pressure (CPAP) machines, have improved treatment adherence among patients with sleep apnea. The integration of artificial intelligence in sleep analysis is also emerging, potentially enhancing the effectiveness of interventions. As these technologies continue to evolve, they are likely to drive growth in the Excessive Daytime Sleepiness Market.

### Growing Awareness of Mental Health

The increasing awareness of mental health issues and their correlation with sleep disorders is driving the Excessive Daytime Sleepiness Market. Mental health conditions, such as depression and anxiety, are often associated with sleep disturbances, leading to excessive daytime sleepiness. As society becomes more attuned to the importance of mental well-being, there is a corresponding rise in the demand for integrated treatment approaches that address both mental health and sleep quality. This awareness is prompting healthcare providers to offer comprehensive solutions that encompass psychological support alongside sleep disorder management. Consequently, the intersection of mental health and sleep health is likely to enhance the growth of the Excessive Daytime Sleepiness Market.

### Impact of Work Culture on Sleep Patterns

The evolving work culture, characterized by longer working hours and increased stress levels, is significantly impacting sleep patterns and contributing to excessive daytime sleepiness. Many individuals are experiencing sleep deprivation due to demanding job requirements and the blurring of work-life boundaries. This trend is particularly evident in high-stress industries, where employees often prioritize work over adequate rest. As awareness of the detrimental effects of sleep deprivation on productivity and overall health grows, organizations are beginning to implement wellness programs that promote better sleep hygiene. This shift in workplace culture is likely to drive the demand for solutions within the Excessive Daytime Sleepiness Market, as both employers and employees seek to address the consequences of inadequate sleep.

### Increasing Prevalence of Sleep Disorders

The rising incidence of sleep disorders, particularly sleep apnea and insomnia, is a primary driver of the Excessive Daytime Sleepiness Market. Studies indicate that approximately 30% of adults experience sleep disturbances, leading to excessive daytime sleepiness. This prevalence is expected to escalate as more individuals seek medical attention for their sleep-related issues. The growing recognition of the link between sleep disorders and chronic health conditions, such as obesity and cardiovascular diseases, further emphasizes the need for effective treatment options. Consequently, healthcare providers are increasingly focusing on diagnosing and managing sleep disorders, thereby propelling the demand for solutions within the Excessive Daytime Sleepiness Market.

## Future Outlook

The Excessive Daytime Sleepiness Market is projected to grow at a 7.2% CAGR from 2025 to 2035, driven by increasing awareness and advancements in treatment options.

**New opportunities:**

- Development of wearable sleep monitoring devices Expansion of telehealth services for sleep disorders Creation of targeted pharmaceutical therapies for EDS

By 2035, the Excessive Daytime Sleepiness Market is expected to achieve substantial growth, reflecting evolving consumer needs and innovative solutions.

## Segment Insights

### By Diseases: Obstructive Sleep Apnea (OSA) (Largest) vs. Narcolepsy (Fastest-Growing)

The Excessive Daytime Sleepiness Market is primarily driven by two significant diseases: Obstructive Sleep Apnea (OSA) and Narcolepsy. Among these, OSA holds a substantial share due to its higher prevalence and awareness, leading to increased diagnosis and treatment rates. Narcolepsy, while less common, is rapidly gaining attention as awareness of its symptoms rises, contributing positively to its market presence. As more patients recognize their condition, the demand for effective treatments is on the rise.

Diseases: OSA (Dominant) vs. Narcolepsy (Emerging)

Obstructive Sleep Apnea (OSA) is the dominant force in the Excessive Daytime Sleepiness Market, characterized by interrupted breathing during sleep. With increased awareness and availability of continuous positive airway pressure (CPAP) devices, OSA treatment options are becoming more accessible. In contrast, Narcolepsy is recognized as an emerging segment, marked by spontaneous daytime sleep attacks and cataplexy. As patient education improves, it is expected to gain significant traction in the market, with novel therapies becoming available. Both conditions highlight the importance of tailored treatment approaches as awareness leads to higher diagnosis rates.

### By Treatment: Therapeutic Drugs (Largest) vs. Devices (Fastest-Growing)

In the Excessive Daytime Sleepiness Market, therapeutic drugs, particularly stimulants and antidepressants, currently hold the largest market share. These pharmaceutical treatments are favored for their effectiveness in addressing the condition, leading to significant adoption amongst patients experiencing excessive daytime sleepiness. Devices, while less prevalent in terms of overall market share, are gaining traction due to advancements in technology and increased awareness of non-pharmaceutical options.

Therapeutic Drugs: Stimulants (Dominant) vs. Devices (Emerging)

Stimulants remain the dominant treatment in the Excessive Daytime Sleepiness Market due to their established efficacy in enhancing wakefulness and concentration. These medications are often prescribed for their rapid action and ability to manage symptoms effectively. On the other hand, devices such as wearable technology and mobile apps are emerging as innovative solutions, appealing to a tech-savvy demographic seeking alternative therapies. As a growing number of consumers prioritize non-pharmaceutical interventions, devices are expected to capture a larger portion of the Excessive Daytime Sleepiness Market, reflecting a shift in consumer preferences towards holistic and integrated treatment options.

### By Distribution channels: Hospitals & Sleep Laboratories (Largest) vs. Home Care Settings (Fastest-Growing)

In the Excessive Daytime Sleepiness Market, the distribution of market share favors Hospitals & Sleep Laboratories, as they continue to be the primary destination for diagnosis and treatment. These facilities offer specialized care with advanced diagnostic tools and expert staff, leading to a significant portion of market activity being concentrated in this sector. Meanwhile, Home Care Settings are rapidly gaining ground, appealing to patients seeking convenience and comfortable environments for symptom management.

Hospitals & Sleep Laboratories (Dominant) vs. Home Care Settings (Emerging)

Hospitals & Sleep Laboratories are critical in managing excessive daytime sleepiness, providing comprehensive diagnostic and therapeutic services. They are well-equipped with cutting-edge technology and staffed by specialists, which drives patient referrals and procedures. On the contrary, Home Care Settings are emerging as a popular alternative, providing patients with flexible treatment options and the comfort of home. This segment is bolstered by growing telemedicine adoption and improved home sleep testing methods, catering to the increasing demand for patient-centric care solutions. Both channels together are reshaping treatment landscapes, addressing diverse patient needs while enhancing overall market growth.

## Regional Market Share Analysis

### North America : Leading Market for Sleep Disorders

North America is the largest market for Excessive Daytime Sleepiness (EDS), accounting for approximately 45% of the global market share. The region's growth is driven by increasing awareness of sleep disorders, rising healthcare expenditure, and advancements in treatment options. Regulatory support from agencies like the FDA has also catalyzed market expansion, facilitating quicker approvals for innovative therapies. The United States is the primary contributor to Excessive Daytime Sleepiness Market, with significant investments from key players such as Jazz Pharmaceuticals and Eli Lilly. Canada follows as the second-largest market, focusing on improving healthcare access and treatment options. The competitive landscape is characterized by a mix of established pharmaceutical companies and emerging biotech firms, all striving to address the growing demand for effective EDS treatments.

### Europe : Emerging Market with Growth Potential

Europe is witnessing a growing demand for Excessive Daytime Sleepiness (EDS) treatments, holding approximately 30% of the global market share. Factors such as increasing prevalence of sleep disorders, heightened awareness, and supportive healthcare policies are driving this growth. The European Medicines Agency (EMA) has been instrumental in streamlining the approval process for new therapies, further enhancing market dynamics. Leading countries in this region include Germany, France, and the UK, which are home to several key players like AstraZeneca and Sanofi. The competitive landscape is evolving, with a mix of established pharmaceutical giants and innovative startups focusing on EDS. Collaborative efforts among stakeholders are also fostering advancements in treatment options, making Europe a promising market for EDS solutions.

### Asia-Pacific : Rapidly Growing Market Segment

The Asia-Pacific region is emerging as a significant player in the Excessive Daytime Sleepiness (EDS) market, accounting for about 20% of the global share. The growth is fueled by increasing urbanization, rising stress levels, and a growing awareness of sleep health. Countries like China and India are witnessing a surge in demand for EDS treatments, supported by government initiatives aimed at improving healthcare access and quality. China leads the Excessive Daytime Sleepiness Market in this region, driven by a large population and increasing healthcare investments. India follows closely, with a growing number of healthcare providers focusing on sleep disorders. The competitive landscape features both local and international players, including Teva Pharmaceutical and Merck, all vying for a share in this rapidly expanding market.

### Middle East and Africa : Untapped Market with Challenges

The Middle East and Africa (MEA) region represents an untapped market for Excessive Daytime Sleepiness (EDS), holding approximately 5% of the global market share. The growth potential is significant, driven by increasing awareness of sleep disorders and a rising prevalence of related health issues. However, challenges such as limited healthcare infrastructure and access to treatments hinder market development. Regulatory bodies are beginning to recognize the importance of addressing sleep disorders, which may catalyze future growth. Countries like South Africa and the UAE are leading the charge in EDS awareness and treatment options. The competitive landscape is still developing, with a few key players like Pfizer and Amgen starting to establish a presence. Collaborative efforts between governments and healthcare organizations are essential to unlock the market's potential and improve treatment accessibility.

## Competitive Benchmarking

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the excessive daytime sleepiness market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, excessive daytime sleepiness industry must offer cost-effective items. Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the excessive Daytime Sleepiness industry to benefit clients and increase the market sector. In recent years, the excessive daytime sleepiness industry has offered some of the most significant advantages. Major players in the excessive daytime sleepiness market, including Teva Pharmaceutical Industries Ltd.,GE Healthcare ,Jazz Pharmaceuticals,CompumedicsFisher & Paykel Healthcare,BIOPROJET,BMC Medical Co. Ltd.,Avadel Pharmaceuticals plc ,Cadwell Laboratories Inc. Ltd ,GlaxoSmithKline plc ,Braebon Medical Corporation ,Pfizer and others, are attempting to increase market demand by investing in research and development operations. Harmony Biosciences Holdings, Inc. was founded in 2017 and is headquartered in Plymouth Meeting, Pennsylvania, USA. The company is dedicated to addressing unmet needs in sleep and CNS disorders, with a focus on bringing transformative Applications to patients.Harmony Biosciences is known for its emphasis on narcolepsy, a sleep disorder characterized by excessive daytime sleepiness. The company has developed and commercialized medications specifically designed to address symptoms associated with narcolepsy. Harmony Biosciences Holdings, Inc. initiated a Phase 3 trial evaluating the efficacy and safety of pitolisant in adult patients with idiopathic [hypersomnia](https://www.marketresearchfuture.com/reports/hypersomnia-market-32317) (IH), known as the INTUNE study. NLS Pharma Ltd. is a biopharmaceutical company dedicated to advancing innovative Applications for central nervous system disorders, with a particular focus on narcolepsy. Privately held, the company is committed to addressing unmet medical needs in the field of neurological and psychiatric conditions through research, development, and the advancement of novel therapies. With a pipeline of drug candidates, NLS Pharma aims to contribute to improved outcomes for patients experiencing symptoms such as excessive daytime sleepiness and cataplexy. NLS pharma Ltd. reported that the European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion to grant Orphan Drug Designation (ODD) for Mazindol ER (Quilience) for the Application of idiopathic hypersomnia (IH).

## Recent News & Developments

**August 2021:**For a new indication of Xywav, Jazz Pharmaceuticals Plc. received USFDA approval (calcium, magnesium, potassium, and sodium oxybates). It is an oral solution used to treat adult patients with idiopathic hypersomnia. It is the first medication that the USFDA has approved for unique use in idiopathic hypersomnia.

**March 2019:**Jazz Pharmaceuticals Plc. received FDA approval for a Sunosi (solriamfetol). The first and only dual-acting dopamine and norepinephrine reuptake inhibitor that has been authorized to treat excessive daytime sleepiness linked to narcolepsy or obstructive sleep apnea.

## Report Scope

| MARKET SIZE 2024 | 5.971(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 6.401(USD Billion) |
| MARKET SIZE 2035 | 12.83(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.2% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Jazz Pharmaceuticals (IE), Eli Lilly and Company (US), Teva Pharmaceutical Industries Ltd. (IL), AstraZeneca (GB), Merck & Co., Inc. (US), Novartis AG (CH), Pfizer Inc. (US), Sanofi (FR), Amgen Inc. (US) |
| Segments Covered | Diseases, Treatment, Distribution channels, Region |
| Key Market Opportunities | Advancements in wearable sleep technology enhance diagnosis and management in the Excessive Daytime Sleepiness Market. |
| Key Market Dynamics | Rising awareness of sleep disorders drives demand for innovative treatments in the Excessive Daytime Sleepiness Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Excessive Daytime Sleepiness Market?**
A: As of 2024, the market valuation was 5.971 USD Billion.

**Q: What is the projected market size for the Excessive Daytime Sleepiness Market by 2035?**
A: The market is projected to reach 12.83 USD Billion by 2035.

**Q: What is the expected CAGR for the Excessive Daytime Sleepiness Market during the forecast period?**
A: The market is expected to grow at a CAGR of 7.2% from 2025 to 2035.

**Q: Which segments are included in the Excessive Daytime Sleepiness Market?**
A: The market includes segments such as Diseases, Treatment, and Distribution Channels.

**Q: What were the valuations for the Obstructive Sleep Apnea segment in 2024 and its projected value in 2035?**
A: The Obstructive Sleep Apnea segment was valued at 3.582 USD Billion in 2024 and is projected to reach 7.56 USD Billion by 2035.

**Q: How does the Narcolepsy segment compare in valuation from 2024 to 2035?**
A: The Narcolepsy segment had a valuation of 2.389 USD Billion in 2024 and is expected to grow to 5.27 USD Billion by 2035.

**Q: What are the projected values for therapeutic drugs in the Excessive Daytime Sleepiness Market?**
A: Therapeutic drugs, including stimulants and sodium oxybate, are projected to grow from 4.471 USD Billion in 2024 to 9.6 USD Billion by 2035.

**Q: Which distribution channel had a valuation of nearly 3 billion USD in 2024?**
A: Both Hospitals & Sleep Laboratories and Home Care Settings had valuations of approximately 2.986 USD Billion and 2.985 USD Billion, respectively, in 2024.

**Q: Who are the key players in the Excessive Daytime Sleepiness Market?**
A: Key players include Jazz Pharmaceuticals, Eli Lilly and Company, Teva Pharmaceutical Industries, and others.

**Q: What is the projected growth for devices used in the treatment of excessive daytime sleepiness?**
A: The devices segment is expected to grow from 1.5 USD Billion in 2024 to 3.2 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/excessive-daytime-sleepiness-market-20304*